Corrected: Innate Immunity All Greek To You? We Can Translate; Init OP, $30 PT

Research evidence excerpt

Corrected: Innate Immunity All Greek To You? We Can Translate; Init OP, $30 PT

Company Report

June 15, 2026 Odyssey Therapeutics (ODTX)

Rating: Corrected: Innate Immunity All Greek To You? We CanOUTPERFORM Translate; Init OP, $30 PTPrice:

$16.96

12-Month Price Target: The Wedbush View

$30.00

(CORRECTION: Figs. 1, 21, 22 updated from S-1)

Analysts

ODTX is a clinical-stage inflammation and immunology (I&I) company developingDavid Nierengarten, Ph.D.

(415) 274-6862 therapeutics primarily against innate immune targets. By targeting key upstream

David.Nierengarten@wedbush.com signaling nodes, ODTX candidates may simultaneously suppress multiple pro-

Martin Fan, Ph.D. inflammatory pathways with applicability across indications. Lead candidate

(213) 688-3404 OD-001 is an oral RIPK2 scaffolding inhibitor that has demonstrated monotherapy

Martin.Fan@wedbush.com efficacy in ulcerative colitis (UC), a large indication with a global estimated 2-3%

Dennis Pak y/y growth rate. Ph 2 placebo-controlled monotherapy and Entyvio combination(415) 263-6647

Dennis.Pak@wedbush.com trials are planned to begin in 2H26, with initial results expected in 2H27. Preclinical

development is underway for multiple additional candidates targeting various

innate signaling nodes, offering pipeline diversification and upside potential. We

Company Information hold a long-term favorable view of ODTX given its novel approaches to target key

Market Cap (M) $808 signaling nodes, broad applicability of each pipeline candidate, and focus on I&IEnterprise Value (M) $631

Shares Outst (M) 47.6 indications with large market potential.

52-Week Range $15.35 - $20.30

Cash/sh $3.70 New approaches to target biology. Prior efforts to target RIPK2 failed because